A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)
Primary Immune Thrombocytopenia
About this trial
This is an interventional treatment trial for Primary Immune Thrombocytopenia
Eligibility Criteria
Inclusion Criteria:
- Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits).
- Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period.
Note: If a participant has had an SAE during the ARGX-113-2004 trial, their eligibility should be evaluated by the investigator and the sponsor's trial physician. The decision of enrolling the participant will be evaluated case by case.
3a. Agree to use contraceptives consistent with local regulations regarding the methods of contraception for those participating in clinical trials and the following:
- Male participants.
- Female participants of childbearing potential must have a negative urine pregnancy test at baseline before receiving IMP.
In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period (only applicable in case efgartigimod is not yet commercially available for patients with primary ITP or available through another patient program for patients with primary ITP), the following criteria apply:
4. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
5. Participant has completed a 52-week treatment period.
Exclusion criteria:
- Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines)
- Use of any other investigational drug or participation in any other investigational trial
- Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients
- Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC
Sites / Locations
- Investigator Site 0010116Recruiting
- Investigator site 0010045Recruiting
- Investigator Site 0010062Recruiting
- Investigator site US0010042Recruiting
- Investigator Site 0010095Recruiting
- Investigator Site 0540001
- Investigator site 540004Recruiting
- Investigator Site 0610012Recruiting
- Investigator Site 0610003Recruiting
- Investigator site 610005Recruiting
- Investigator Site 3590017Recruiting
- Investigator site 0560003Recruiting
- Investigator site 560002Recruiting
- Investigator site 0560004Recruiting
- Investigator site 860013Recruiting
- Investigator Site 0860008Recruiting
- Investigator site 860055Recruiting
- Investigator Site 0860015Recruiting
- Investigator Site 0860001Recruiting
- Investigator Site 0860010Recruiting
- Investigator Site 0860002Recruiting
- Investigator Site 0860011Recruiting
- Investigator site 860058Recruiting
- Investigator Site 9950007Recruiting
- Investigator site 9950009Recruiting
- Investigator site 9950011Recruiting
- Investigator site 300008Recruiting
- Investigator Site 0300009Recruiting
- Investigator site 3530003Recruiting
- Investigator site 390043
- Investigator Site 0390032Recruiting
- Investigator Site 0390044Recruiting
- Investigator site 390041
- Investigator site JP0810015Recruiting
- Investigator Site 0810017Recruiting
- Investigator Site 0810053Recruiting
- Investigator Site 0810051Recruiting
- Investigator site 0810016Recruiting
- Investigator site 810023Recruiting
- Investigator Site 0810038Recruiting
- Investigator site 9620001Recruiting
- Investigator site 820004Recruiting
- Investigator site KO0820007Recruiting
- Investigator site 520002Recruiting
- Investigator site 640005Recruiting
- Investigator site 0470003Recruiting
- Investigator site PL0480013Recruiting
- Investigator Site 0480026Recruiting
- Investigator Site 0480037Recruiting
- Investigator Site 3510007Recruiting
- Investigator site 3510004Recruiting
- Investigator site 3510001Recruiting
- Investigator Site 0400005Recruiting
- Investigator site 400012Recruiting
- Investigator Site 0400007Recruiting
- Investigator site 0070040Recruiting
- Investigator Site 0070026
- Investigator Site 0070038Recruiting
- Investigator Site 0070037Recruiting
- Investigator site 270003Recruiting
- Investigator site 270004Recruiting
- Investigator site 270001Recruiting
- Investigator site 270002Recruiting
- Investigator Site 0660001Recruiting
- Investigator Site 0660002Recruiting
- Investigator Site 0660003Recruiting
- Investigator site 660005Recruiting
- Investigator site 0660004Recruiting
- Investigator site TH0660009Recruiting
- Investigator site 2610001Recruiting
- Investigator site 2160002Recruiting
- Investigator Site 0900007Recruiting
- Investigator Site 0900003Recruiting
- Investigator Site 0900008Recruiting
- Investigator Site 0900015Recruiting
- Investigator site 900004Recruiting
- Investigator Site 0900014Recruiting
- Investigator site 900010Recruiting
- Investigator site 0900017Recruiting
- Investigator site 900019Recruiting
- Investigator site 440005Recruiting
- Investigator site UK044041Recruiting
- Investigator site UK0440014Recruiting
Arms of the Study
Arm 1
Experimental
efgartigimod PH20 SC
Patients receiving efgartigimod PH20 SC treatment